Back to Journals » Drug Design, Development and Therapy » Volume 11

Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up

Authors Dixon DL, Buckley LF, Trankle CR, Kadariya D, Abbate A

Received 30 April 2017

Accepted for publication 20 June 2017

Published 11 July 2017 Volume 2017:11 Pages 2121—2129

DOI https://doi.org/10.2147/DDDT.S114091

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 3

Editor who approved publication: Dr Tuo Deng

Dave L Dixon,1 Leo F Buckley,1 Cory R Trankle,2 Dinesh Kadariya,3 Antonio Abbate2

1Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, 2Pauley Heart Center, 3Department of Internal Medicine, School of Medicine, Virginia Commonwealth University, Richmond, VA, USA

Abstract: Inhibition of PCSK9 is a novel therapeutic strategy aimed at reducing low-density-lipoprotein cholesterol (LDL-C) and cardiovascular risk. Evolocumab is a fully humanized monoclonal antibody that inhibits PCSK9, an enzyme that binds to LDL receptors and prevents them from recycling to the hepatocyte surface. Clinical trials have demonstrated 50%–70% reductions in LDL-C with evolocumab when used in combination with statin therapy. The recent FOURIER trial demonstrated that evolocumab further reduces cardiovascular events, but not mortality, in high-risk patients already receiving statin therapy. Furthermore, evolocumab did not affect neurocognitive function and was not associated with antidrug-antibody production in over 60,000 patient-years of drug exposure. Appropriate candidates for evolocumab primarily are individuals at high cardiovascular risk, including those with familial hypercholesterolemia and/or established cardiovascular disease, who are already on statin therapy. At this time, the use of evolocumab monotherapy seems appropriate only for individuals deemed statin-intolerant despite attempting several statins. Consideration must be given toward patient willingness to self-inject evolocumab and issues concerning third-party coverage, given the current costs of evolocumab.

Keywords: evolocumab, PCSK9, familial hypercholesterolemia, hyperlipidemia

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]